Zura Bio Limited (NASDAQ:ZURA) Receives Consensus Rating of "Buy" from Brokerages

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) has received an average rating of "Buy" from the eight analysts that are covering the firm, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $14.67.

A number of brokerages recently issued reports on ZURA. Chardan Capital dropped their price objective on shares of Zura Bio from $12.00 to $10.00 and set a "buy" rating for the company in a report on Wednesday, March 26th. HC Wainwright reaffirmed a "buy" rating on shares of Zura Bio in a research report on Thursday, April 3rd. Guggenheim reissued a "buy" rating and set a $15.00 target price on shares of Zura Bio in a research note on Wednesday, March 26th. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $19.00 price target (down previously from $20.00) on shares of Zura Bio in a research note on Wednesday, March 26th.

Zura Bio Stock Down 4.5 %

Shares of Zura Bio stock traded down $0.07 during trading hours on Tuesday, reaching $1.47. 303,306 shares of the company's stock were exchanged, compared to its average volume of 387,568. The business has a fifty day moving average of $1.27 and a two-hundred day moving average of $2.25. The company has a market capitalization of $100.51 million, a P/E ratio of -2.77 and a beta of 0.08. Zura Bio has a 1 year low of $0.97 and a 1 year high of $6.35.

Zura Bio (NASDAQ:ZURA - Get Free Report) last posted its quarterly earnings results on Tuesday, March 25th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.09. The company had revenue of $0.00 million during the quarter. As a group, research analysts predict that Zura Bio will post -0.65 EPS for the current year.

Hedge Funds Weigh In On Zura Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of ZURA. American Century Companies Inc. acquired a new stake in shares of Zura Bio during the fourth quarter worth about $27,000. Prudential Financial Inc. acquired a new stake in Zura Bio during the 4th quarter worth approximately $28,000. Two Sigma Advisers LP acquired a new position in shares of Zura Bio in the fourth quarter worth $32,000. ProShare Advisors LLC purchased a new stake in shares of Zura Bio during the fourth quarter worth $35,000. Finally, XTX Topco Ltd acquired a new stake in shares of Zura Bio in the fourth quarter valued at $44,000. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.